The psychedelic sector never sits still. Here is what happened during the week of January 12–18, 2026, and why each story matters for the companies and investors we track.
Definium Therapeutics, Inc. (formerly MindMed) (DFTX): MindMed unveils full rebrand as Definium Therapeutics, spotlighting late-stage LSD pipeline
Mind Medicine (MindMed) relaunched as Definium Therapeutics, a new corporate name and brand identity meant to distance the company from its 2021 'shroom-stock' vintage and reframe it as a rigorous late-stage psychiatry developer. Management emphasized a pipeline led by DT120 ODT (its optimized LSD/lysergide tartrate), with three Phase 3 readouts across major depressive disorder and generalized anxiety disorder expected during 2026. The move made Definium the second advanced psychedelic drug developer to rebrand in early 2026, after Cybin became Helus Pharma days earlier.
Source: finance.yahoo.com
Definium Therapeutics, Inc. (formerly MindMed) (DFTX): Company's Nasdaq ticker switches from MNMD to DFTX
Following the corporate rebrand, the company's common shares began trading on Nasdaq under the new symbol DFTX, replacing MNMD. The ticker change completed the transition to the Definium Therapeutics identity for investors. The rebrand carried over the existing share structure with a one-for-one continuation.
Source: miaxglobal.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.